BioNTech

2 articles

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

BioNTech reduced its 2026 revenue guidance to €1.6-1.9 billion due to softening COVID vaccine demand, with Q2 revenue falling over 50%. The German pharma company also appointed a new CEO and plans to

reuters · 2026-08-04 04:02

Moderna Interested in Germany Production, Sees Opportunity in BioNTech Closures, Says CEO

Moderna CEO Stephane Bancel expressed interest in acquiring BioNTech's planned-to-close German production facilities, citing them as a cost-effective alternative to new builds pending government partn

reuters · 2026-06-16 23:38